ATE468129T1 - Glutation vorlaeufer zur behandlung von neuropsychiatrisschen krankheiten - Google Patents

Glutation vorlaeufer zur behandlung von neuropsychiatrisschen krankheiten

Info

Publication number
ATE468129T1
ATE468129T1 AT02799377T AT02799377T ATE468129T1 AT E468129 T1 ATE468129 T1 AT E468129T1 AT 02799377 T AT02799377 T AT 02799377T AT 02799377 T AT02799377 T AT 02799377T AT E468129 T1 ATE468129 T1 AT E468129T1
Authority
AT
Austria
Prior art keywords
treatment
nervous system
central nervous
present
glutation
Prior art date
Application number
AT02799377T
Other languages
English (en)
Inventor
Ashley Bush
David Copolov
Michael Berk
Original Assignee
Mental Health Res Inst Of Vict
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23266273&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE468129(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mental Health Res Inst Of Vict filed Critical Mental Health Res Inst Of Vict
Application granted granted Critical
Publication of ATE468129T1 publication Critical patent/ATE468129T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02799377T 2001-09-27 2002-09-26 Glutation vorlaeufer zur behandlung von neuropsychiatrisschen krankheiten ATE468129T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32506101P 2001-09-27 2001-09-27
PCT/AU2002/001320 WO2003026684A1 (en) 2001-09-27 2002-09-26 Modulation of physiological processes and agents useful for same

Publications (1)

Publication Number Publication Date
ATE468129T1 true ATE468129T1 (de) 2010-06-15

Family

ID=23266273

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02799377T ATE468129T1 (de) 2001-09-27 2002-09-26 Glutation vorlaeufer zur behandlung von neuropsychiatrisschen krankheiten

Country Status (10)

Country Link
US (3) US20050032708A1 (de)
EP (1) EP1438063B1 (de)
JP (3) JP4684553B2 (de)
AT (1) ATE468129T1 (de)
AU (1) AU2002333018B2 (de)
CA (1) CA2461703C (de)
DE (1) DE60236446D1 (de)
DK (1) DK1438063T3 (de)
ES (1) ES2346859T3 (de)
WO (1) WO2003026684A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040057983A1 (en) * 2002-09-25 2004-03-25 David Schmidt Biomolecular wearable apparatus
WO2005017094A2 (en) * 2003-08-19 2005-02-24 Bioadvantex Pharma Inc. N-acetyl compositions as adjunct therapy for treatment and prevention of cysteine/glutathione deficiency
US20100099762A1 (en) * 2006-10-23 2010-04-22 The Mental Health Research Institute Of Victoria Combination therapy
US7829709B1 (en) 2007-08-10 2010-11-09 Marquette University Cysteine prodrugs to treat schizophrenia and drug addiction
IL188681A0 (en) * 2008-01-09 2008-12-29 Amino Acid Solutions Inc Pharmaceutical compositions and methods utilizing a d-amino acid
US8173809B2 (en) * 2008-02-07 2012-05-08 Marquette University Cysteine and cystine prodrugs to treat schizophrenia and reduce drug cravings
US8602961B2 (en) * 2008-05-15 2013-12-10 Lifewave Products Llc Apparatus and method of stimulating elevation of glutathione levels in a subject
WO2010132864A1 (en) * 2009-05-15 2010-11-18 Intermune, Inc. Methods of treating hiv patients with anti-fibrotics
US8355927B2 (en) 2010-11-05 2013-01-15 Genomind, Llc Neuropsychiatric test reports
WO2012024293A2 (en) * 2010-08-16 2012-02-23 Genomind, Llc Medical foods for the treatment of developmentally-based neuropsychiatric disorders via modulation of brain glycine and glutathione pathways
US20120270860A1 (en) * 2011-04-19 2012-10-25 Gihyun Yoon Methods for treating or preventing alcohol-related disorders or craving-related disorders
AU2013339057B2 (en) 2012-10-30 2018-08-30 Kyowa Hakko Bio Co., Ltd. Agent for preventing or improving decline in brain function
EP3066089B1 (de) 2013-11-08 2019-11-06 Promentis Pharmaceuticals, Inc. Substituierte n-acetyl-l-cystein-derivate und verwandte verbindungen
AU2015317877A1 (en) * 2014-09-15 2017-05-04 Sound Pharmaceuticals Incorporated Methods and compositions for treating psychotic disorders
WO2020067228A1 (ja) * 2018-09-28 2020-04-02 学校法人慶應義塾 併用抗がん剤の感受性の判定マーカー
EP4061387A1 (de) * 2019-11-18 2022-09-28 Société des Produits Nestlé S.A. Zusammensetzungen und verfahren zur glutathionverbesserung zur verwendung in der gehirngesundheit
FR3119093B3 (fr) * 2021-01-27 2023-02-10 Nestle Sa Compositions et procedes pour une utilisation dans l’augmentation de la performance motivationnelle

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5922765A (en) * 1996-01-18 1999-07-13 Fleming & Company, Pharmaceuticals Methods and compositions for the prevention and treatment of muscle cramps and improving muscular strength
US5874468A (en) * 1996-12-26 1999-02-23 Yissum Brain targeted low molecular weight hydrophobic antioxidant compounds
US6149925A (en) * 1998-11-05 2000-11-21 Color Access, Inc. Topical compositions for enhancing glutathione production
US6329430B1 (en) * 1999-08-18 2001-12-11 Thomas Jefferson University Modulation of N-methyl-D-aspartate receptor responses with S-substituted derivatives of glutathione
US20020002146A1 (en) * 2000-02-11 2002-01-03 Halevie-Goldman Brian D. Compositions and methods for the production of S-adenosylmethionine within the body
US20020002136A1 (en) * 2000-06-28 2002-01-03 Hebert Rolland F. Salts of glutathione
AU2001271824A1 (en) * 2000-07-05 2002-01-14 Johns Hopkins School Of Medicine Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes
GB0017060D0 (en) * 2000-07-11 2000-08-30 Hunter Fleming Ltd Production, stabilisation and use of reduced forms of pharmaceutical compounds
GB2368339B (en) * 2000-10-26 2002-09-18 Yissum Res Dev Co Complex incorporating a plurality of antioxidants

Also Published As

Publication number Publication date
JP2005508333A (ja) 2005-03-31
JP5736421B2 (ja) 2015-06-17
EP1438063B1 (de) 2010-05-19
EP1438063A1 (de) 2004-07-21
DK1438063T3 (da) 2010-08-30
JP4684553B2 (ja) 2011-05-18
CA2461703A1 (en) 2003-04-03
CA2461703C (en) 2011-04-05
ES2346859T3 (es) 2010-10-21
JP2010215646A (ja) 2010-09-30
AU2002333018B2 (en) 2006-08-31
US20130065961A1 (en) 2013-03-14
WO2003026684A1 (en) 2003-04-03
US20180177839A1 (en) 2018-06-28
JP2013234193A (ja) 2013-11-21
US20050032708A1 (en) 2005-02-10
EP1438063A4 (de) 2006-05-31
DE60236446D1 (de) 2010-07-01

Similar Documents

Publication Publication Date Title
DE60236446D1 (de) Glutation vorlaeufer zur behandlung von neuropsychiatrisschen krankheiten
ATE462427T1 (de) Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren
ATE307592T1 (de) Epiallopregnanolon zur behandlung von krankheiten des cns
ATE337780T1 (de) Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
EP1592689A4 (de) 3-amino-4-phenylbutansäurederivate als dipeptidylpeptidase-hemmer zur behandlung oder vorbeugung von diabetes
MXPA04003796A (es) Tioacetamidas sustituidas.
DE60237635D1 (de) Verwendung von pramipexol zur behandlung von amyotrophischer lateralsklerose
DE69428791D1 (de) Verwendung vonModafinil zur Behandlung von Atemstillstand im Schlaf und zentral erregten Atembeschwerden
ATE392208T1 (de) Zusammensetzungen zur prävention und behandlung von erkältung und grippe-ähnlichen symptomen, die cheliertes zink enthalten
DE60328816D1 (de) Prozess zur verminderung des acrylamidgehaltes von hitzebehandelten lebensmitteln
DE69805672D1 (de) Verwendung von Rifaximin als Medikament zur Behandlung von durch Cryptosporidiose verursachten Diarrhoeen
DE60228278D1 (de) Die verwendung von potenten, selektiven und nontoxischen c-kithemmern zur behandlung von interstitieller blasenentzündung
ATE390928T1 (de) Zusammensetzungen zur behandlung von hauterkrankungen
DE60231107D1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
DE602004023762D1 (de) Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3-thiosubstituierte indol-2-alkinsäuren
DE60234246D1 (de) Cannabinoiden zur behandlung von während des schlafens auftretenden atmungsstörungen
ATE298568T1 (de) Albumin-bindende verbindungen die die nichtenzymatische glycosylierung verhindern und die zur behandlung von glycosylierungsbedingten erkrankungen verwendet werden können
TW200509937A (en) Novel compounds and their use in therapy
NO20054744L (no) Behandling av Alzheimers sykdom
AU8647101A (en) Compounds having activity as inhibitors of cytochrome p450rai
ATE363474T1 (de) Benzimidazole zur behandlung sexueller fehlfunktionen
MY139368A (en) Novel cyclohexyl sulphones
ATE304855T1 (de) Verwendung von olanzapin zur behandlung von mentalen erkrankungen verursacht durch zerebrovaskuläre erkrankungen
ATE334693T1 (de) Verwendung von tyrosine-kinase inhibitoren zur behandlung von cns krankheiten
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties